Phase 3 Trial Will Examine Mesdopetam as Treatment for Levodopa-induced Dyskinesia

Phase 3 Trial Will Examine Mesdopetam as Treatment for Levodopa-induced Dyskinesia
Integrative Research Laboratories (IRLAB) is planning a Phase 2b/3 clinical trial of its investigational therapy mesdopetam (IRL790) to evaluate the therapy’s ability to reduce levodopa-induced dyskinesia (involuntary muscle movements) in people with Parkinson’s disease. IRLAB is in the process of preparing applications to relevant regulatory agencies, with plans to start the trial in the second half of this year. “The strategy ... read more
Source: Parkinson’s News TodayPublished on 2020-06-11By Marisa Wexler